Thor Equities has announced the launch of Thor Sciences, a division specializing in the Life Sciences sector.
The announcement comes on the heels of Thor’s $152 million acquisition of The Center of Excellence, a 784,000 s/f campus that spans 48 acres located in Bridgewater, New Jersey.
Comprised of laboratory, research and development, and office buildings, the complex features life science companies specializing in pharmaceuticals and health services including anchor tenants Nestlé Health Science, Ashland, and Amneal Pharmaceuticals.
Additional tenants include Insmed, Avantor, Nevakar, Solaris Pharma, Clinical Genomics, Matinas BioPharma, Vertice Pharma, 3D Biotek, Unionmed Tech and GSG Scientific.
Expansion plans for The Center of Excellence are expected to be in excess of tens of millions of dollars.
A key player in The Center of Excellence acquisition, and unveiling of Thor’s global platform, is Bill Hunter, senior vice president of Thor Sciences.
Hunter has over 20 years of experience in the life science and higher-education verticals. He has executed approximately $4 billion in acquisitions and millions of square feet of strategic campus re-positioning projects for major life science and university campus developments in scientific clusters covering the U.S. coastlines from Boston to Miami and San Francisco to San Diego.
“We are pleased to announce the launch of Thor Sciences as well as the acquisition of The Center of Excellence,” said Thor’s chairman and CEO, Joseph Sitt.
“We have been an early advocate for the sector, having previously acquired assets in Berkeley and Boston, and are now ready to advance our global platform with the appointment of Life Sciences expert and new senior vice president.